Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy

Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

“…Evidence is inconsistent as to whether the use of abatacept, compared with other b/tsDMARDs, is associated with an increased risk of malignancy [27,28,[34][35][36]. Contrary to the results of previous population-based cohort studies, which included evaluations of all NMSC [35] and squamous cell skin cancer [37], no significantly increased risk of NMSC was observed with abatacept compared with other b/tsDMARDs in this study.…”

“…Contrary to the results of previous population-based cohort studies, which included evaluations of all NMSC [35] and squamous cell skin cancer [37], no significantly increased risk of NMSC was observed with abatacept compared with other b/tsDMARDs in this study. The results of this study are consistent with those from a meta-analysis of clinical trials that showed b/tsDMARDs, including abatacept, were not significantly associated with an increased malignancy risk compared with csDMARDs or placebo [36]. Previous interventional trials and real-world analyses of abatacept demonstrated a similar malignancy risk of abatacept compared with placebo or other comparators [27,28,34].…”

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study

“…In our study, the IR for malignancy was 1.06/100 PY in patients with RA treated using IL-6is. Our results are consistent with those of previous studies ( 16 ).…”

Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study

“…Our data does not predict increased incidence of EBV associated lymphoma in RA patients under Tocilizumab therapy. This seems to be in accordance with safety data: a meta-analysis did not show LPD enhancement under Tocilizumab, even after one year [ 38 ]. Only one case of EBV reactivation has been described in Japan under Tocilizumab therapy [ 44 ].…”